novo nordisk cuts prices for its glp-1 drugs. to Cut U.S. List Ozempic, Wegovy by Up to 50% Novo Nordisk launches Wegovy weight-loss

It embraced them

p = 0.001), fatal and non-fatal myocardial infarction (HR 0.90, 95% CI: 0.830.98

Although we sought to further elucidate the sources of heterogeneity, subgroup analyses based on sex, BMI, or other covariates could not be performed because too few studies and insufficient data were available

And finally, this is not the last GLP-1 drug

Decreased risk of anxiety in diabetic patients receiving glucagon-like peptide-1 receptor agonist: a nationwide, population-based cohort Study

In summary, although biological plausibility is strong, evidence in MSA is restricted to one animal model and one small clinical study